Alercell
Private Company
Total funding raised: $4.2M
Overview
Alercell is a private, early-stage diagnostics company developing an AI-driven epigenetic platform for the ultra-early detection of leukemia and other cancers. Founded in 2018 and headquartered in New York, the company's bold claim is the ability to detect leukemia risk up to 41 months before symptom onset, targeting a paradigm shift from reactive treatment to proactive prevention. As a pre-revenue entity, its success hinges on clinical validation, regulatory approval, and market adoption of its novel diagnostic approach.
Technology Platform
AI-driven epigenetic diagnostics platform analyzing molecular signatures (e.g., DNA methylation) from blood to predict cancer risk years before symptoms.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Alercell competes in the emerging field of liquid biopsy for early cancer detection. Direct competitors include large players like Grail (Illumina) and Exact Sciences developing multi-cancer tests, though Alercell's focus on leukemia and claimed long lead time is a key differentiator. It also faces competition from academic research initiatives and other epigenetics-focused diagnostics startups.